BioCentury
ARTICLE | Clinical News

Wilson upgraded after final Phase II copper readout

April 24, 2017 11:09 PM UTC

Wilson Therapeutics AB (SSE:WTX) revealed final data from the Phase II WTX101-201 study of Decuprate bis-choline tetrathiomolybdate (WTX101) to treat Wilson's disease, in which excess copper accumulates in the body. DNB Markets analyst Patrik Ling raised the company's target price to SEK135 from SEK80 on the news, and Wilson shares jumped SEK18 (30%) to SEK77.25 on Monday.

Wilson plans to begin Phase III testing of Decuprate next half. In December, the company said Decuprate met the Phase II trial's primary endpoint. The candidate is a second-generation analog of ammonium tetrathiomolybdate (see BioCentury Extra, Dec. 5, 2016). ...

BCIQ Company Profiles

Wilson Therapeutics AB

BCIQ Target Profiles

Superoxide dismutase 1 (SOD1)